LKFT Lakefront Biotherapeutics N.V.

QT80

Latest market price

32.17

+0.15+0.47%

Overview Short InterestFilings

LKFTQT80Lakefront Biotherapeutics N.V.·NASDAQ

Overview Short InterestFilings

32.17+0.47%

Loading chart...

Signal & projected range

Analyst consensus risingHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

BCRX+1.27%$8.35 PVLA+2.12%$149.43 ZYME+2.70%$29.77 VCEL+0.19%$40.59 AUPH+1.21%$16.34 VERA-0.07%$30.23 SEPN+1.74%$43.95 XNCR+1.72%$30.17

Snapshot

Index	—	P/E	3.04	EPS (ttm)	10.52	Insider Own	—	Shs Outstand	65.48M	Perf Week	1.04%

Market Cap	2.10B	Forward P/E	—	EPS next Y	-2.69	Insider Trans	—	Shs Float	40.94M	Perf Month	9.02%

Enterprise Value	2.06B	PEG	—	EPS next Q	-0.93			Short Float	3.46%	Perf Quarter	21.06%

Income	694.00M	P/S	1.82	EPS this Y	—			Short Ratio	5.15	Perf Half Y	12.51%

Sales	1.15B	P/B	0.56	EPS next Y	—	ROA	14.49%	Short Interest	1.42M	Perf YTD	-2.08%

Book/sh	56.70	P/C	0.82	EPS next 5Y	—	ROE	16.88%	52W High	36.24 -11.23%	Perf Year	2.17%

Cash/sh	39.02	P/FCF	—	EPS past 3/5Y	—	ROIC	11.61%	52W Low	25.68 25.27%	Perf 3Y	-1.75%

Dividend Est.	—	EV/EBITDA	5.30	Sales past 3/5Y	70.32% —	Gross Margin	98.01%	Volatility	2.09% 2.37%	Perf 5Y	-37.89%

Dividend TTM	—	EV/Sales	1.76	EPS Y/Y TTM	—	Oper. Margin	36.43%	ATR (14)	0.74	Perf 10Y	-51.29%

Dividend Ex-Date	—	Quick Ratio	30.30	Sales Y/Y TTM	284.67%	Profit Margin	46.83%	RSI (14)	65.99	Recom	2.50

Dividend Gr. 3/5Y	—	Current Ratio	30.48	EPS Q/Q	101.86%	SMA20	4.50%	Beta	0.20	Target Price	35.50

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-81.08%	SMA50	8.35%	Rel Volume	0.91	Prev Close	32.02

Employees	452	LT Debt/Eq	0.00	Earnings	Nov 11	SMA200	7.05%	Avg Volume	285.80K	Price	32.17

IPO Date	May 05, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	103.61% 94.17%	Net Debt/EBITDA	-4.08	Volume	259,066	Change	0.47%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-23-26	Upgrade	RBC Capital	Sector Perform → Outperform	$45
Aug-11-26	Reiterated	Morgan Stanley	Equal Weight	$30 → $26
Jul-10-26	Resumed	Morgan Stanley	Equal Weight	$30

Latest News· Times ET

Nov-02-26

Nov-02-2604:01PM

Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directorsglobenewswire.com

Oct-22-26

Oct-22-2602:45AM

Oncocyte (NASDAQ:IMDX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Analysisdefenseworld.net

Oct-21-26

Oct-21-2601:01PM

Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?zacks.com

01:16AM

Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Looks Undervalued Despite A 40% Five Year FallYahoo

Oct-15-26

Oct-15-2611:55AM

Belgian startup revives Galapagos CAR-T researchYahoo

Oct-14-26

Oct-14-2604:01PM

Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeuticsglobenewswire.com

Oct-13-26

Oct-13-2604:01PM

Acquisition of Own Sharesglobenewswire.com

Oct-08-26

Oct-08-2604:01PM

Lakefront Receives Transparency Notification from Bank of AmericaYahoo

Oct-06-26

Oct-06-2604:01PM

Acquisition of Own Sharesglobenewswire.com

Sep-29-26

Sep-29-2604:01PM

Acquisition of Own Sharesglobenewswire.com

Sep-23-26

Sep-23-2609:49AM

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst callsYahoo

Sep-22-26

Sep-22-2604:01PM

Acquisition of Own Sharesglobenewswire.com

Sep-21-26

Sep-21-2605:02AM

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamigmarketbeat.com

Sep-15-26

Sep-15-2610:01PM

Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha

04:01PM

Acquisition of Own Sharesglobenewswire.com

Company

Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021
Total Revenue	1,154	1,255	298	259	—	—
Cost of Goods Sold Incl. D&A	60	34	38	0	—	—
Gross Profit	1,095	1,221	261	259	—	—
Selling, General and Administrative Excl. Other	126	126	105	102	—	—
Research and Development	277	518	363	261	—	—
Other Operating Expense	-18	12	-4	-8	—	—
Operating Income	709	566	-204	-95	—	—
Interest Expense	0	3	1	2	—	—
Unusual Expense	—	—	—	—	—	—
Non-Operating Income (Expense)	-38	-224	201	103	—	—
Net Income Before Taxes	671	339	-3	6	—	—
Income Taxes	-19	-21	-2	10	—	—
Consolidated Net Income	694	362	80	229	—	—
Net Income From Continuing Operations	691	360	-1	-4	—	—
Net Income	694	362	80	229	—	—
EPS (Recurring)	10.52	5.49	1.21	3.47	—	—
EPS (Basic, Before Extraordinaries)	10.52	5.49	1.21	3.47	—	—
EPS (Diluted)	10.52	5.49	1.21	3.47	—	—
EBITDA	625	405	47	55	—	—
Other After Tax Adjustments	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—
Price To Earnings Ratio	3.06	5.95	22.69	11.71	—	—
Price To Sales Ratio	1.84	1.72	6.09	10.36	—	—
Gross Margin	94.89	97.29	87.58	100.00	—	—
Operating Margin	61.44	45.10	-68.46	-36.68	—	—
Net Margin	60.14	28.84	26.85	88.42	—	—
Shares Outstanding	66	66	66	66	—	—
Market Capitalization	2,123	2,158	1,815	2,683	—	—
Operating Lease Expense	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.